In Friday’s Wall Street session, Medtronic Plc (NYSE:MDT) shares traded at $89.94, up 2.27% from the previous session.
MDT stock price is now 4.73% away from the 50-day moving average and 5.57% away from the 200-day moving average. The market capitalization of the company currently stands at $115.33B.
With the price target enhanced from $98 to $105, RBC Capital Mkts Upgraded its rating from Sector Perform to Outperform for Medtronic Plc (NYSE: MDT). On August 21, 2024, Oppenheimer reiterated its ‘Perform’ rating on the stock by increasing its target price from $92 to quote $94, while ‘UBS’ rates the stock as ‘Neutral’
In other news, Wall Brett A., EVP & Pres Neuroscience sold 12,437 shares of the company’s stock on Jan 24 ’25. The stock was sold for $1,119,330 at an average price of $90.00. Upon completion of the transaction, the EVP & Pres Neuroscience now directly owns 40,979 shares in the company, valued at $3.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 24 ’25, Officer Wall Brett A. bought 12,437 shares of the business’s stock. A total of $1,119,330 was incurred on buying the stock at an average price of $90.00. A total of 0.14% of the company’s stock is owned by insiders.
During the past 12 months, Medtronic Plc has had a low of $75.96 and a high of $93.08. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 1.90, and a quick ratio of 1.43.
The net profit margin was 12.83% and return on equity was 8.42% for MDT. The company reported revenue of $8.4 billion for the quarter, compared to $7.98 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.25 percent. For the current quarter, analysts expect MDT to generate $8.81B in revenue.
